Synthon (rights of glatiramer acetate) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Synthon (rights of glatiramer acetate) General Information
Description
The commercialization rights of glatiramer acetate in the United States. It is a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Pharmaceuticals
Acquirer
Primary Office
- P.O. Box 110487
- Research Triangle Park
- Durham, NC 27709
- United States
Synthon (rights of glatiramer acetate) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|